Today, I'll briefly focus my comments on our financial commitments for 2025 and how we are leading through a dynamic ...

Thank you, Mark, and good afternoon. Following my remarks, Jim Watkins will review our financial performance in more detail, ...

Amid the surging wave of innovation in China's biopharmaceutical industry, a decade is long enough to witness the full evolution of a sector—from its initial emergence and growth to fundamental ...